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tasis and recurrence in gastric cancer, and the prognosis is
extremely poor due to the resistance of systemic chemotherapy.
Here, we demonstrate that intraperitoneal (i.p.) administration
of a green fluorescence protein (GFP)-expressing attenuated
adenovirus with oncolytic potency (OBP-401) synergistically
suppressed the peritoneal metastasis of gastric cancer in
combination with paclitaxel (PTX). OBP-401 synergistically
suppressed the viability of human gastric cancer cells in
combination with PTX. PTX enhanced the antitumor effect of
OBP-401 due to enhanced viral replication in cancer cells. The
combination therapy increased induction ofmitotic catastrophe,
resulting in accelerated autophagy and apoptosis. Peritoneally
disseminated nodules were selectively visualized as GFP-positive
spots by i.p. administration of OBP-401 in an orthotopic human
gastric cancer peritoneal dissemination model. PTX enhanced
the deep penetration of OBP-401 into the disseminated nodules.
Moreover, a non-invasive in vivo imaging system demonstrated
that the combination therapy of i.p. OBP-401 administration
with PTX significantly inhibited growth of peritoneal metastatic
tumors and the amount of malignant ascites. i.p. virotherapy
with PTX may be a promising treatment strategy for the perito-
neal metastasis of gastric cancer.Received 3 June 2020; accepted 22 June 2020;
https://doi.org/10.1016/j.omto.2020.06.021.
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Peritoneal metastasis is the most common form of distant metastasis
and recurrence in gastric cancer, and the prognosis remains extremely
poor, even with current advanced modalities.1–3 At present, no cura-
tive treatment options exist for peritoneal metastasis. Systemic palli-
ative chemotherapy is generally administered to patients with perito-
neal metastasis.4,5 Systemic administration of anti-cancer drugs is
limited for the treatment of peritoneal carcinomatosis because the
peritoneal-plasma barrier prevents the delivery of anti-cancer drugs
from the blood into the peritoneal cavity.6,7 Intraperitoneal (i.p.)
administration of chemotherapeutic agents is advantageous for peri-
toneal carcinomatosis compared to systemic chemotherapy because
anti-cancer drugs can be directly delivered into the peritoneal cavity,
and high concentrations can be maintained in the peritoneal cavity.262 Molecular Therapy: Oncolytics Vol. 18 September 2020 ª 2020 Th
This is an open access article under the CC BY license (http://creatiSeveral phase III trials have demonstrated that i.p. chemotherapy
has a survival benefit compared with systemic chemotherapy in
patients with advanced ovarian cancer.8–10 In gastric cancer with peri-
toneal metastasis, some phase II trials have demonstrated the effec-
tiveness of i.p. paclitaxel (PTX), which can be retained in the perito-
neal cavity for a long time due to its molecular characteristics
including its large size and water insolubility, in addition to systemic
chemotherapy.11–13 Recently, a phase III trial has suggested the pos-
sibility of improved survival of i.p. PTX with systemic chemo-
therapy.14 However, the outcome of gastric cancer patients with peri-
toneal metastasis is unsatisfactory, and new or improved strategies are
needed.
Oncolytic viruses are designed to replicate selectively within tumor
cells and lyse infected tumor cells.15We have developed an attenuated
adenovirus (Ad), OBP-301 (Telomelysin), which drives the E1A and
E1B genes for viral replication under control of the human reverse
transcriptase promoter, and we previously confirmed its antitumor
effects in various human tumor cells including gastric cancer.16–19
Furthermore, a phase I trial of OBP-301 for patients with various
advanced solid tumors demonstrated that OBP-301 is well tolerated
by patients.20 We have further developed OBP-401 (TelomeScan),
which is a modified OBP-301, to express green fluorescent protein
(GFP) to visualize viable cancer cells.21–23 OBP-401 enables detection
of a few viable cancer cells as GFP-positive cells in the clinical perito-
neal washes of advanced gastrointestinal cancer patients.23,24
Although systemic virotherapy is impractical due to the presence of
neutralizing antibodies for Ad, locoregional administration such as
to an intratumoral site or the i.p. cavity is a reasonable strategy.25
In this study, we show that i.p. administration of OBP-401 results in




Figure 1. OBP-401 Synergistically Enhances the Antitumor Effect of PTX in Human Gastric Cancer Cells
(A) GCIY and KATOIII cells were infected with OBP-401 at the indicated MOIs for 3 days. Cells were treated with PTX at the indicated doses for 24 h. Cell viability was
quantified using the XTT assay. The cell viability of a mock-treated group was considered 1.0, and the relative cell viability was calculated. Data are expressed as the mean ±
SD (n = 5). (B) For monotherapy, cells were infected with OBP-301 at the indicated MOIs for 72 h or treated with PTX at the indicated concentrations for 24 h. For combination
therapy with OBP-301 and PTX, GCIY cells were infected with OBP-301 at the indicated MOIs. 2 days after viral infection, cells were treated with PTX (0.1 mmol/L) for 24 h.
Cell viability and cytotoxicity were evaluated using the live and dead assay. Green color indicates live cells, and red color indicates dead cells. Scale bar, 200 mm. (C) The
combination index was calculated with CalcuSyn software. Synergism and antagonism were defined as interaction indices of <1 and >1, respectively.
www.moleculartherapy.orggastric cancer. Furthermore, the antitumor activity of OBP-401 was
markedly enhanced when used in combination with PTX, which
enhanced the replication and penetration of OBP-401 in peritoneal
metastasis of gastric cancer.
RESULTS
In Vitro Synergistic Antitumor Effect of OBP-401 and PTX on
Human Gastric Cancer Cells
Previously, we developed an oncolytic Ad, OBP-401 (TelomeScan),
which replicates selectively only within human cancer cells and ex-
presses GFP.21,23 To evaluate the antitumor effect of OBP-401 and
PTX, which is effective for peritoneal metastasis of gastric and ovarian
cancer following i.p. administration,8–14 we treated GCIY or KATOIII
cells with OBP-401 or PTX. Cell death was induced in both GCIY and
KATOIII cells in a dose-dependent manner following treatment with
OBP-401 or PTX (Figure 1A). We reported the chemosensitizing ef-
fect of OBP-301, which has the same basic structure as OBP-401except for GFP (Figure S1), in several types of human malignant tu-
mor cells.26–29 To investigate the synergistic antitumor effect of OBP-
401 and PTX in human gastric cancer cells, we evaluated the effect of
combination therapy visually using a live and dead assay. We used
OBP-301 instead of OBP-401 to distinguish live cells from dead cells
in this experiment. The cytopathic effect of OBP-301 on human
gastric cancer cells was equal to that of OBP-401 (Figure S2). Combi-
nation therapy suppressed the viability of GCIY and KATOIII
cells more efficiently than monotherapy (Figure 1B; Figure S3).
The sodium 30-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) cell viability
assay also demonstrated that combination therapy induced gastric
cancer cell death in a dose-dependent manner. Calculation of the
combination index indicated a synergistic antitumor effect of combi-
nation therapy in both types of human gastric cancer cells (Figure 1C).
These results suggest that the combination of OBP-401 and PTX has a
synergistic antitumor effect on human gastric cancer cells.Molecular Therapy: Oncolytics Vol. 18 September 2020 263
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Figure 2. PTX Enhances the Replication Efficiency of
OBP-401 in Human Gastric Cancer Cells
(A) Time-lapse imaging of GCIY cells treated with OBP-401,
PTX, or both. Green color indicates OBP-401 replication, and
red color indicates PTX uptake. Scale bar, 50 mm. (B)
Expression of adenoviral E1A proteins in GCIY and KATOIII
cells treated with OBP-401 and PTX. b-actin was used as a
loading control. The band intensity of E1A was normalized
against that of b-actin and the ratios are shown. (C)
Assessment of viral replication in GCIY cells. GCIY cells were
treated with OBP-401 (1MOI) or the combination of OBP-401
(1 MOI) and PTX (0.1 mM). Quantitative real-time PCR assay
was performed to quantify the amount of viral E1A copy
number. The copy number of viral E1A is defined as the E1A/
GAPDH ratio relative to that of the sample 2 h after OBP-401
infection (2 h after OBP-401 infection = 1). Data are shown as
means ± SD. Statistical significance was defined as p < 0.05
(single asterisk).
Molecular Therapy: OncolyticsEnhancement of Adenoviral Replication Efficiency in Human
Gastric Cancer Cells by PTX
To investigate the mechanism underlying the synergistic antitumor
effect of OBP-401 and PTX, we assessed whether PTX affects the
replication of OBP-401 in human gastric cancer cells. For this pur-
pose, GCIY cells treated with 10 nM PTX conjugated with red fluores-
cence were simultaneously infected with 10 multiplicity of infection
(MOI) OBP-401, and the uptake of green and red fluorescence into
the cancer cells was evaluated with time-lapse imaging. Red PTX fluo-
rescence was immediately taken up into the cytoplasm of cancer cells.
The replication of OBP-401 in the cancer cells was detected as GFP
expression 24 h after virus administration. When combined with
PTX, the number of GFP-expressing cells infected with OBP-401
was increased compared to monotherapy (Figure 2A; Video S1).
Next, we performed western blot analysis and quantitative real-time
PCR assay of viral E1A to assess whether PTX enhances the replica-
tion efficiency of OBP-401 in gastric cancer cells. Western blot anal-
ysis showed that the expression of adenoviral E1A was increased by
the combination with PTX compared to monotherapy (Figure 2B).
Moreover, quantitative PCR assay showed that the copy number of
viral E1A was increased by the combination with PTX (Figure 2C).
These results suggest that PTX enhances the replication efficiency
of OBP-401 in human gastric cancer cells and synergistically en-
hances adenoviral oncolysis.
Increase in MC Induction by the Combination of PTX and
Oncolytic Ad
To evaluate the underlying mechanism of the synergistic antitumor
effect of oncolytic Ad and PTX, we analyzed the effects of combined
treatment on cell-cycle progression. GCIY cells were infected with
OBP-401, and 2 days after OBP-401 infection, cells were treated
with PTX. 24 h after PTX treatment, fluorescence-activated cell sort-264 Molecular Therapy: Oncolytics Vol. 18 September 2020ing (FACS) analyses were performed. Monother-
apy with PTX increased the number of cells in
the G2/M phase and multi-nuclear cells, although10 MOI of OBP-401 infection alone did not notably alter the cell-cy-
cle profile (Figure 3A). Combination therapy with OBP-401 and PTX
enhanced the accumulation of cells in the G2/M phase and multi-nu-
clear cells. Accordingly, we further analyzed the nuclear morphology
of multi-nuclear cells because we expected that multi-nuclear cells
were related to the synergistic effects of combination treatment of hu-
man gastric cancer cells.
Mitotic catastrophe (MC) is a distinctive process of cell death caused
by abnormal mitosis.30 MC is characterized by unique morpholog-
ical nuclear alterations such as multi-nucleation and/or micro-
nucleation. 24 h after treatment, multi-nucleated giant nuclei with
chromosome vesicles were observed in cells treated with PTX or
OBP-301. When cells were treated with a combination of OBP-
301 and PTX, giant multi-nucleated cells and micro-nucleated cells
were observed (Figure 3B). Evaluation of MC development was per-
formed by counting nuclei displaying morphological changes char-
acteristic of MC. The combination of OBP-301 and PTX signifi-
cantly increased MC induction in human gastric cancer cells
(Figure 3C). This result suggests that MC is related to the synergistic
antitumor effect of combination therapy for human gastric cancer
cells.
Enhancement of OBP-401-InducedApoptosis and Autophagy by
PTX
To evaluate whether MC induction with combination therapy can
prime or accelerate cancer cells to different types of cell death, we
used western blot analysis to assess induction of apoptosis and auto-
phagy after treatment. Western blot analysis was performed 72 h after
OBP-401 infection and revealed that OBP-401 or PTX treatment
increased apoptosis, as confirmed by the accumulation of cleaved




Figure 3. The Combination of Oncolytic Ad and PTX Increases Induction of Mitotic Catastrophe (MC)
(A) The percentage of cells in each phase of the cell cycle was analyzed using FACS analysis in GCIY cells stained with propidium iodide after mock treatment or treatment
with OBP-401, PTX, or the combination of OBP-401 and PTX. GCIY cells were infected with OBP-401 at a dose of 10 MOI. 2 days after OBP-401 infection, cells were treated
with PTX at a dose of 0.1 mM for 24 h. The percentage of cells in G1, S, and G2/M and multi-nuclear cells were analyzed with FACS analysis. Data are expressed as mean
values ± SD (n = 3). (B) Representative images of MC-associated nuclear morphology of GCIY cells 24 h after treatment with OBP-301, PTX, or both. Blue color indicates the
nucleus, and green color indicates b-tubulin. Scale bar, 10 mm. (C) The percentage of MC was quantified from three different randomly selected fields under a confocal laser
scanning microscope. Data are expressed as mean values ± SD. Statistical significance was defined as *p < 0.05.
www.moleculartherapy.orgAssessment of p62 downregulation revealed that OBP-401 infection
stimulated autophagy, although PTX treatment did not (Figure 4A).
When combined with PTX, OBP-401 enhanced expression of cleaved
PARP compared to monotherapy. Moreover, when combined with
PTX, p62 was downregulated by a lower dose of OBP-401 compared
to monotherapy (Figure 4B). These results suggest that apoptosis and
autophagy were accelerated by combination therapy as a result of MC
induction.
Labeling Peritoneal Carcinomatosis with OBP-401 and Selective
Replication in Disseminated Nodules
To verify that OBP-401 injected into the abdominal cavity could
infect peritoneal metastatic nodules and selectively replicate within
them, we injected 500 mL solution containing OBP-401 into the
abdominal cavity of nude mice bearing peritoneal carcinomatosis
of human gastric cancer. 7 days after virus injection, disseminated
nodules were detected as GFP fluorescence with fluorescence im-
aging (Figure 5A). Moreover, immunohistochemical staining re-
vealed that the adenoviral E1A protein was selectively expressed
in disseminated nodules, but not in surrounding visceral organs
including liver (Figure 5B). These results suggest that i.p. injectionof OBP-401 selectively infected and labeled peritoneal dissemi-
nated cancer.
i.p. Virotherapy Combined with PTX for Peritoneal
Carcinomatosis
Finally, we examined whether i.p. administration of OBP-401 com-
bined with PTX could eradicate peritoneal disseminated cancer using
a GCIY-Luc xenograft mouse model, because KATOIII cells do not
have tumorigenic ability. OBP-401 or PBS was i.p. injected 17 days
after tumor inoculation. PTX was i.p. injected 2 days after OBP-401
injection for only one cycle. The combination of OBP-401 and PTX
significantly suppressed i.p. tumor growth compared to PBS or
monotherapy with OBP-401 or PTX (Figures 6A and 6B). Histopath-
ological examination of resected peritoneal nodules showed that
adenovirus in the combination therapy-treated tumors infiltrated
more deeply into the tumor compared to OBP-401-treated tumors
(Figure 6C; Figure S7). Moreover, 2 weeks after treatment, the
amount of fluid in the abdominal cavity in the virotherapy groups
was significantly decreased compared to PBS or PTX treatment (Fig-
ure 6D). These results suggest that i.p. virotherapy has therapeutic po-
tential to eradicate peritoneal carcinomatosis of gastric cancer, andMolecular Therapy: Oncolytics Vol. 18 September 2020 265
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Figure 4. PTX Enhances OBP-401-Induced Apoptosis
and Autophagy by Increasing MC
(A) Expression of PARP, cleaved PARP (C-PARP), and p62
proteins in GCIY and KATOIII cells treated with PTX at the
indicated doses. Expression of PARP, C-PARP, p62, and
adenoviral E1A proteins in cells infected with OBP-401 at
the indicated MOIs. (B) Expression of PARP, C-PARP, p62,
and adenoviral E1A proteins in GCIY cells treated with
OBP-401 and PTX at 0.1 mM. b-actin was used as a loading
control.
Molecular Therapy: Oncolyticsthat PTX enhances the antitumor effect of OBP-401 for peritoneal
metastasis.
DISCUSSION
At present, existing treatments for peritoneal dissemination of gastric
cancer have not significantly improved clinical outcomes. In this study,
we demonstrated the therapeutic potential of i.p. administration of
OBP-401 in combination with PTX for peritoneal dissemination of
gastric cancer. i.p. administration of antitumor agents is a reasonable
and effective treatment strategy for peritoneal metastasis because these
agents can directly reach i.p. cancer cells. In our previous studies, we
performed intra-tumoral injection of OBP-301 into primary tumor
sites and showed that the tumor-specific, replication-selective
oncolytic Ad, OBP-301, has antitumor effects in various types of can-
cers.16,18–20,31 Moreover, we have shown that i.p. administration of
OBP-301 could spread to the peritoneal cavity and infect viable cancer
cells,23,32 resulting in antitumor effects on peritoneal metastasis.28
In preclinical studies, the efficacy of an oncolytic Ad combined with
chemotherapeutic agents such as docetaxel, gemcitabine, Cisplatin
(CDDP), doxorubicin, and PTX in several human cancer cells has
been previously reported.27–29,33,34 OBP-301 and OBP-401 enhance
the antitumor effects of chemotherapeutic agents. However, anti-
DNA synthesis agents such as gemcitabine, CDDP, and doxorubicin
may have deleterious effects on viral replication because adenoviral
E1A directs the progression of host cells from the G1/G0 phase to the
S phase to optimize viral DNA replication. On the other hand, PTX is
an antimicrotubular agent that stabilizes microtubules by preventing
depolymerization and arrests the cell cycle in the G2 andM phases,35,36
which induces apoptosis, but does not inhibit DNA synthesis of host
cells. Therefore, PTX is suitable for combination use with oncolytic Ad.
The combination of an Ad-mediated agent and taxanes has synergistic
or additive effects in several cancers.27,33,37,38 However, the mechanism266 Molecular Therapy: Oncolytics Vol. 18 September 2020of the combination effect of these agents is unclear.
We demonstrated that OBP-401 induced cancer
cell lysis in vitro, and its effect was markedly
enhanced by the combination with PTX (Figure 1).
Western blot analysis and time-lapse imaging
showed that PTX enhanced the replication effi-
ciency ofOBP-401 in gastric cancer cells (Figure 2).
However, with flow cytometry analysis, weobservedno increase in coxsackie adenovirus receptor expression,which
is the primary receptor for Ad, when gastric cancer cells were treated
with PTX (data not shown). PTX enhances adenoviral particle assembly
and release, which results in synergistic effects on cancer cells.38,39 PTX
may help Ad assembly in a microtubule-dependent manner because
PTX increases the binding ability of Ad capsids to microtubules.40
PTX induces cell-cycle arrest in the G2/M phase as we showed with
flow cytometry analysis (Figure 3A). The combination with OBP-
401 and PTX increased the percentage of cancer cells in the G2/M
phase. This observation suggests that OBP-401 enhances the percent-
age of cancer cells that enter PTX-mediated G2/M arrest by compul-
sive cell-cycle mobilization and G2/M trapping. Recently, we also
reported that oncolytic Ad virus enhances the antitumor effects of
quiescent cancer stem-like cells by induction of cell-cycle reentry.19
Oncolytic Ad virus directly damages DNA and causes aberrant
mitosis in cancer cells, which results in MC. Moreover, multi-nuclear
cells were increased with combination therapy.
MC is a novel oncosuppressive mechanism that senses mitotic failure
and results in an irreversible fate of death such as apoptosis, autophagy,
and necrosis in cancer cells.30,41MC is not a separatemode of cell death
but a process that decides how the cell will die.42 Microtubule-targeting
agents such as PTX are well-known antimitotic agents, which induce
MC by microtubule polymerization.43 The characteristic morpholog-
ical changes ofMCwere detected following PTX treatment (Figure 3B).
OBP-301 also induced MC in human gastric cancer cells, although
wild-type Ad and replication-deficient Ad did not (Figure S4). This
result suggests that OBP-401 directly damages the DNA of host cancer
cells and forces them into cycling, which results in induction ofMC and
enhances the sensitivity of cancer cells to PTX.
The safety and feasibility of intratumoral injection of OBP-301 in pa-
tients with various types of advanced solid tumors have already been
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Figure 5. i.p. Injection of OBP-401 Allowed Selective
Visualization of Peritoneal Dissemination of GCIY
Cells and Replication
(A) 4 weeks after inoculation of GCIY cells into the perito-
neal cavity, 1  105 PFU of OBP-401 was injected into the
peritoneal cavity. 5 days later, disseminated nodules were
visualized with GFP fluorescence. Scale bar, 1 mm. (B)
Histological analysis of tissue sections of various organs.
Upper panel, H&E staining. Scale bar, 200 mm. Lower
panel, immunohistochemical staining for adenoviral E1A
protein showing selective replication within peritoneal tu-
mor cells. The nuclei were counterstained with hematox-
ylin. Positive staining is reddish brown (blue arrowheads).
Scale bar, 200 mm.
www.moleculartherapy.orgconfirmed in a phase I clinical trial.20 Furthermore, phase I/II clinical
studies of OBP-301 in combination with radiation therapy for esopha-
geal cancer patients showed preliminary efficacy with no dose-limiting
toxicities. Some phase I trials of i.p. administration of oncolytic virus
have been performed in patients with ovarian cancer,44–46 and their
safety profiles were confirmed. The safety of i.p. administration of
PTX has been also confirmed in phase III trial for gastric cancer patients
withperitonealmetastasis.14Therewasno effectof each treatmenton the
body weight of mice in vivo study (Figure S5).We and our collaborators
have confirmed that i.p. administrationofOBP-301 in combinationwith
CDDP has therapeutic efficacy for peritoneal metastasis of ovarian can-
cer in a xenograft model. In this study, i.p. administration of OBP-401
allowed selective visualization of disseminated nodules, and viral E1A
protein was not detected in any other visceral organs (Figure 5), which
indicates that i.p. virotherapy using OBP-401 has minimal adverse ef-
fects on normal i.p. organs. Furthermore, a dose-titration study (Fig-
ure S6) indicated that OBP-401 at 105 plaque-forming units (PFUs),
which is 3 logs lower than the concentration used for intratumoral injec-
tion, could still effectively suppress peritoneal dissemination, suggesting
that i.p. administration of OBP-401 may easily lead to virus dispersion
over the abdominal cavity and effective attachment to the disseminated
nodules. Interestingly, PTX enhanced the penetration of OBP-401 into
the disseminated nodules compared to OBP-401 alone (Figure 6C).
One possible explanation for the deep penetration of OBP-401 by
PTX may be that PTX enhanced the replication ability of OBP-401 in
the disseminatednodules as we showed in vitro. Another possible reason
is that OBP-401may easily infiltrate into the peritoneal nodules because
PTX decreases stromal fibrosis in human peritoneal mesothelial cells.47
Several times of treatmentmight cure the peritonealmetastasis of gastric
cancer although only one cycle of treatment could not. Recently, we have
reported that telomerase-specific oncolytic Ad virus such as OBP-301
could induce immunogenic cell death (ICD), which leads to the induc-
tion of systemic anti-tumor immune response via the activation of den-
dritic cells and the facilitation of cytotoxic T lymphocyte recruitment.48Molecular TheTherefore, i.p. administration of oncolyticAd virus
treatment might be a promising candidate for
combination therapy with immune checkpoint in-
hibitors (ICIs) in the future. Indeed, i.p. adminis-
tration of OBP-401 in combination with PTXsignificantly decreasedmalignant ascites, which indicates that this novel
treatment may not only improve the survival of patients with peritoneal
metastasis but also maintain the quality of life of patients.
In conclusion, we demonstrated that i.p. administration of the telo-
merase-specific, replication-selective Ad, OBP-401, in combination
with PTX efficiently eradicated peritoneal dissemination of gastric
cancer in an orthotopic xenograft model. Moreover, the combination
of OBP-401 and PTX strongly enhanced MC induction due to
compulsive cell-cycle mobilization of OBP-401. Future clinical trials
of i.p. virotherapy in combination with PTX for peritoneal metastasis
are warranted to investigate the efficacy and tolerability.
MATERIALS AND METHODS
Cell Lines
Two human gastric cancer cell lines were used in this study. GCIY cells
were obtained from RIKEN Cell Bank (Tsukuba, Japan), and KATOIII
cells were obtained from Health Science Research Resources Bank
(Osaka, Japan). GCIY cells weremaintained in Eagle’s minimum essen-
tial medium supplemented with 15% heat-inactivated fetal bovine
serum (FBS; Sigma-Aldrich, St. Louis, MO, USA). KATOIII cells
were maintained in a 1:1 mixture of Eagle’s minimum essential
medium and RPMI 1640 supplemented with 10% FBS. GCIY cells
transfected with the firefly luciferase plasmid vector (GCIY-Luc)
were maintained in Eagle’s minimum essential medium supplemented
with 15% FBS containing 0.2 mg/mL Geneticin (G418; Invitrogen,
Carlsbad, CA, USA). All media were supplemented with 100 U/mL
penicillin and 100mg/mL streptomycin. The cells were routinelymain-
tained at 37C in a humidified atmosphere with 5% CO2.
Recombinant Ad and Chemotherapeutic Agent
The recombinant, telomerase-specific, replication-competent Ad
vector OBP-301 (Telomelysin) was previously constructed and
characterized.16–18 OBP-401 (TelomeScan) is a telomerase-specific,rapy: Oncolytics Vol. 18 September 2020 267
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Figure 6. Enhancement of Antitumor Effects of i.p. Administration of OBP-401 in Combination with PTX in the Peritoneal Carcinomatosis Mouse Model of
Gastric Cancer
GCIY-Luc cells (5  106 cells) were inoculated into the abdominal cavity of athymic nude mice. A 500 mL volume of solution containing OBP-401 (1  105 PFU) was i.p.
injected into the abdominal cavity at 17 days after tumor inoculation. PTX (10 mg/kg body weight) was also i.p. injected 2 days after OBP-401 injection. (A) Representative
photographs of tumor-bearingmice treated with PBS, OBP-401, PTX, or OBP-401, and PTX. (B) The luminescence in tumor tissue was analyzed using the IVIS system at 15,
18, 21, 25, and 28 days after tumor inoculation. Data are expressed as mean values ± SD (n = 6). Statistical significance was defined as *p < 0.05. (C) Histological analysis of
peritoneal nodules of GCIY tumors. Tumor tissues were obtained at 28 days after tumor inoculation. Left, H&E staining. Scale bar, 200 mm. Right, immunohistochemical
staining for adenoviral E1A protein. Scale bar, 200 mm. (D) Peritoneal ascites were measured with computed tomography (CT) at 35 days after tumor inoculation. The amount
of ascites was calculated at the fifth lumbar level on CT using ImageJ software. Data are expressed as themean values ±SD (n = 4). Statistical significancewas defined as *p <
0.05.
Molecular Therapy: Oncolyticsreplication-competent Ad variant in which the replication cassette
and GFP under control of the cytomegalovirus promoter were in-
serted into the E3 region for monitoring of viral replication.21,49
The E1A-deleted Ad vector lacking a cDNA insert (dl312) and
wild-type Ad (OBP-202) were also used as control vectors. Viruses
were purified by ultracentrifugation using CsCl step gradients. Viral
titers were determined by a plaque-forming assay using 293 cells,
and the virus was stored at80C. PTX was purchased from Nippon
Kayaku (Tokyo, Japan) and dissolved in PBS.
Cell Viability Assay
GCIY and KATOIII cells were seeded on 96-well plates at a density of
1  103 cells/well and cultured for 24 or 72 h before viral infection or
administration of PTX. For monotherapy, cells were infected with
OBP-401 at MOIs of 0, 1, 10, 25, 50, or 100 PFUs/cell for 72 h, or268 Molecular Therapy: Oncolytics Vol. 18 September 2020treated with PTX at a concentration of 0, 0.01, 0.05, 0.1, 0.25, or
0.5 mmol/L for 24 h. For combination therapy with OBP-401 and
PTX, 48 h after viral infection with OBP-401 at the indicated
MOIs, cells were further treated with PTX for 24 h. Cell viability
was examined by using the Cell Proliferation Kit II (Roche Molecular
Biochemicals, Indianapolis, IN, USA), which is based on a sodium 30-
[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)
benzene sulfonic acid hydrate (XTT) assay, according to themanufac-
turer’s protocol. The combination index was calculated with Calcu-
Syn software (BioSoft, Cambridge, UK). Computation of the combi-
nation index was based on the methods of Chou and Talalay.50
Live and Dead Assay
Cells were seeded on an ultra-low attachment, round-bottom 96-well
plate (Corning Costar, Sigma-Aldrich) at a density of 5  103 cells/
www.moleculartherapy.orgwell and cultured for 24 or 72 h before viral infection or administra-
tion of PTX. For monotherapy, cells were infected with OBP-301 at
the indicated MOIs for 72 h or treated with PTX at the indicated con-
centrations for 24 h. For combination therapy, after 48 h of viral infec-
tion, cells were further treated with PTX (0.1 mmol/L). After 24 h of
PTX administration, cell viability and cytotoxicity were evaluated
with a solution of Calcein (4 mM) and EthD-1(4 mM) dissolved in
PBS. Cells that formed spheroids were imaged using a confocal laser
scanning microscope (LSM780, Zeiss, Jena, Germany).
Evaluation of MC
Cells were seeded for 72 h on a chamber slide (Thermo Fisher Scien-
tific, Waltham, MA, USA) and conjugated with OBP-301, PTX, or
both for 24 h. After each treatment, cells were fixed for 15 min in
4% formaldehyde at room temperature. Protein blocking was done
with 5% bovine serum albumin-PBS for 10 min at room temperature
followed by incubation with b-tubulin antibody (Cell Signaling Tech-
nology, Danvers, MA, USA) for 24 h at 4C. Alexa Fluor 488 anti-rab-
bit secondary antibody (Thermo Fisher Scientific) was then applied
for 60 min at room temperature. Nuclear morphology was counter-
stained by using VECTASHIELD Hardset Antifade Mounting Me-
dium with DAPI (Vector Laboratories, Burlingame, CA, USA). The
morphological changes of the nuclei and cytoskeleton were examined
under a LSM780 confocal laser scanning microscope (Zeiss). Images
were processed with Imaris 7.6 (Bitplane, Belfast, UK).
Cell-Cycle Analysis
GCIY cells were seeded on six-well plates at a density of 10  104
cells/well and cultured for 24 h. After culturing for 24 h, cells were in-
fected with OBP-401 (10 MOI), and after 48 h of viral infection, cells
were further treated with PTX (0.1 mM). After 24 h of PTX adminis-
tration, cells were resuspended and analyzed with FACScan (BD
FACSLyric, BD Biosciences, Franklin Lakes, NJ, USA). The fluores-
cence-activated cell sorting (FACS) data were further analyzed using
FlowJo Software (BD Biosciences) to calculate each fraction of cells in
G1, S, and G2/M phases.
Western Blot Analysis
GCIY and KATOIII cells were seeded in a 100-mm dish at a density of
1  105 cells/dish and infected with OBP-401 at the indicated MOIs
for 72 h. Cells were treated with PTX at the indicated doses for 24 h.
Whole-cell lysates were prepared with lysis buffer (50 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1% Triton X-100) containing a protease in-
hibitor cocktail (Complete Mini; Roche Applied Science, Mannheim,
Germany). Proteins were electrophoresed on 8%–15% sodium do-
decyl sulfate polyacrylamide gels and transferred to polyvinylidene
difluoride membranes (Hybond-P; GE Healthcare, Buckinghamshire,
UK). The membranes were blocked with Blocking-One (Nacalai Tes-
que, Kyoto, Japan) at room temperature for 30 min. The primary
antibodies used were as follows: mouse anti-Ad5 E1A monoclonal
antibody (BD PharMingen, Franklin Lakes, NJ, USA), rabbit anti-
PARP polyclonal antibody, mouse anti-p62 antibody, and mouse
anti-b-actin monoclonal antibody (Sigma-Aldrich). The secondary
antibodies used were as follows: horseradish peroxidase-conjugatedantibodies against rabbit IgG (GE Healthcare), mouse IgG (GE
Healthcare), or goat IgG (Chemicon International, Temecula, CA,
USA). Immunoreactive bands on the blots were visualized using
enhanced chemiluminescence substrates (ECL Plus; GE Healthcare).
The band intensities of E1A were analyzed by ImageJ software (NIH,
Bethesda, MD, USA).
Time-Lapse Imaging
Cells were seeded in a 27-mm glass base dish at a density of 3  104
cells/well and cultured for 7 days. 7 days after cell seeding, cells were
treated with OBP-401 (1 MOI) and PTX (0.1 mM), which was conju-
gated with red fluorescence (P7501; BODIPY FL paclitaxel, Thermo
Fisher Scientific). Time-lapse images were taken serially at hourly in-
tervals for 48 h after treatment using a confocal laser scanning biolog-
ical microscope with a built-in culture incubator (FV-10i, Olympus,
Tokyo, Japan).
Quantitative Real-Time PCR Analysis
GCIY cells were treated with OBP-401 (1MOI) or the combination of
OBP-401 (1 MOI) and PTX (0.1 mM). Total RNA (2 h and 48 h after
treatment) was isolated from cells using the RNeasy Mini kits
(QIAGEN, Hilden, Germany) according to the manufacturer’s in-
structions. The cDNAwas synthesized from 1.0 mg of total RNA using
Advantage RT PCR-kit (Clontech Laboratories, Mountain View, CA,
USA). The quantitative real-time PCR was performed for gene
expression analysis using the StepOnePlus Real-Time PCR System
(Applied Biosystems,Waltham,MA, USA) with Taqman PCRmaster
mix (Applied Biosystems, Foster City, CA, USA). The primers used in
this study were: GAPDH (Applied Biosystems) and E1A (E1A-F: 50-
CCTGAGACGCCCGACATC-30, E1A-R: 50-GGACCGGAGTCAC
AGCTATCC-30). GAPDH was used as a normalization control.
The relative expression of each mRNA was determined using the
DDCt method.
Animal Experiments
Animal experimental protocols were approved by the Ethics Review
Committee for Animal Experimentation of Okayama University
School of Medicine (number OKU-2015275). GCIY-Luc cells (5 
106 cells) were inoculated into the abdominal cavity of 6-week-old
female BALB/c nu/nu mice (CLEA Japan, Tokyo, Japan). 17 days
after cell inoculation, 500 mL solution containing OBP-401 (1 
105 PFU) or PBS was i.p. injected once. PTX (10 mg/kg body
weight) was also i.p. injected 2 days after OBP-401 injection. Six
mice were used for each group. To monitor tumor progression,
we i.p. injected the substrate luciferin (Vivo Glo Luciferin; Promega,
Madison, WI, USA) at a dose of 200 mg/kg body weight. Images
were collected in the supine position every few min after luciferin
injection with the Xenogen in vivo imaging system (IVIS) Lumina
Imaging System (Caliper Life Sciences, Cheshire, UK), and photons
emitted from the abdominal cavity were quantified by using Xeno-
gen Living Image Software (Caliper Life Science). Peritoneal ascites
and metastasis were measured by computed tomography (CT)
35 days after cancer cell inoculation. CT scanning was performed
by 60-slice CT (Latheta LCT-200, HITACHI, Tokyo, Japan). TheMolecular Therapy: Oncolytics Vol. 18 September 2020 269
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ing ImageJ software. To monitor the replication of OBP-401 in the
peritoneal cavity, we took in vivo fluorescence images at laparotomy
using an Olympus SZX16 microscope and a DP71 camera
(Olympus).Immunohistochemistry
For histological studies, peritoneal tumor nodules and visceral organs
were removed and fixed in 10% neutralized formalin. All tissues were
subsequently dehydrated in alcohol, embedded in paraffin, and
sectioned for hematoxylin and eosin staining and immunohistochem-
ical examination. After deparaffinization and rehydration, antigen
retrieval was performed by microwave irradiation in 10 mM citrate
buffer (pH 6.0). Following quenching of endogenous tissue peroxi-
dases, tissue sections were incubated with rabbit anti-E1A polyclonal
antibody (Santa Cruz Biotechnology, Dallas, TX, USA) or rabbit anti-
adenovirus mAb (Abcam, Cambridge, MA, USA) to detect prolifer-
ating viral particles. Immunoreactive signals were visualized with a
3,39-diaminobenzidine tetrahydrochloride solution, and the nuclei
were counterstained with hematoxylin. Sections were viewed under
a microscope (BX50; Olympus).Statistical Analysis
We used the Student’s t test to identify statistically significant differ-
ences between groups. All data are expressed as means ± standard de-
viation (SD). p values less than 0.05 were considered statistically
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